Health

Accelerating progress in global cancer treatment

September 18, 2023

Global

Accelerating progress in global cancer treatment

September 18, 2023

Global
David Humphreys

Global Practice Lead, Health Policy

David Humphreys is the Global Practice Lead for Health Policy at Economist Impact. This practice area offers high quality clinical and health policy analyses that inform micro level health decision making and produce macro level perspective. Through a multidisciplinary group of experts, he and his team support clients across the health ecosystem on such issues as evidence reviews of health interventions, value based healthcare approaches and impact of new policy initiatives.
 
David has held multiple roles at the EIU, first as the Americas Director of Custom Research managing a business that delivered projects on public policy and market strategy, and then as the Head of EIU Healthcare in the US. Prior to the EIU, he was a senior director at Frost & Sullivan, where he led strategic intelligence projects in industries such as Technology and Healthcare, and spearheaded the firm’s expansion in Latin America. He also served as a senior adviser at Management Partners, a consulting firm for US municipal governments, and a junior economist at FIEL, an economic think-tank in Argentina.

Cancer remains a critical health and societal issue with rising incidence rates, delays in care delivery during the pandemic and the number of lives it impacts worldwide. The renewed focus on promising innovations and personalised approaches opens an exciting path forward, though there are risks to falling back into past siloed behaviours and entrenched positions. Our most recent work in oncology research distils these challenges to offer actionable roadmaps for future success—whether that be in the latest therapies, the needs of key demographics or the circumstances affecting different regions.

Cell and Gene Therapies (CGTs): Health system progress in moving from cutting edge to common practice

Sponsored by Gilead

This study reviews the current availability of CGTs and estimates future numbers of therapies that are likely to come onto the market up to 2031. Understand the challenges the technology presents to various healthcare actors and explore a scorecard which examines how well prepared nine countries (Australia, Canada, France, Germany, Italy, Japan, Spain, UK and US) are for rolling out CGTs.

Impact and opportunity: the case for investing in women’s cancers in Asia Pacific

Sponsored by APAC Women's Cancer Coalition and Roche

The burden of women’s cancer (specifically breast and cervical cancer) is examined in six countries in the APAC region: India, Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Using a benchmarking scorecard, thise research examines and compares the quality of policies and programmes to tackle cancer based on recommendations set by the World Health Organisation (WHO).

Rising to the metastatic breast cancer (MBC) challenge: current and future policy responses

Sponsored by Sanofi

This report highlights the diversity of challenges that people with MBC face around the world. It further identifies priorities for policymakers, advocacy organisations, health system administrators and other key stakeholders to improve the quality of life for individuals with MBC.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week